Cigna earnings beat by $0.04, revenue topped estimates
BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage oncology company with a market capitalization of $9.49 million and currently trading below its InvestingPro Fair Value, announced today ongoing progress in its Phase 1a clinical trial of TTX-MC138, a therapeutic candidate intended to treat metastatic cancer by targeting a specific microRNA associated with the disease’s progression. So far, 13 patients have been treated with TTX-MC138 without any significant safety or dose-limiting toxicities.
The trial involves escalating doses of TTX-MC138, ranging from 0.8 mg/kg to 4.8 mg/kg. Two of the participants have maintained stable disease for at least seven months after receiving seven doses of the treatment. These results are consistent with the drug’s preclinical and initial Phase 0 clinical trial outcomes. According to InvestingPro data, the company maintains a healthy current ratio of 2.56 and holds more cash than debt, though it is rapidly burning through its cash reserves.
The Phase 1a trial is part of a larger study that includes a subsequent dose-expansion phase to further evaluate the safety and potential anti-tumor activity of TTX-MC138. The primary goal of the current phase is to assess the drug’s safety and tolerability.
TransCode’s TTX-MC138 is a first-in-class candidate designed to inhibit microRNA-10b, which is widely believed to play a critical role in many metastatic cancers. The company’s earlier Phase 0 trial provided evidence that even a microdose of TTX-MC138 can reach metastatic lesions and exhibit pharmacodynamic activity.
The current trial is a multicenter, open-label study that aims to provide critical safety and tolerability data for TTX-MC138 in patients with various metastatic solid cancers. Although not a primary endpoint, the trial may also offer early indications of the drug’s clinical efficacy.
TransCode is a clinical-stage oncology company committed to developing RNA therapeutics to treat metastatic disease. The company’s lead therapeutic candidate, TTX-MC138, is focused on metastatic tumors that overexpress microRNA-10b.
The information in this article is based on a press release statement. Further details on the trial can be found on the clinicaltrials.gov website under identifier NCT06260774.
In other recent news, TransCode Therapeutics, Inc. has reported significant progress in its Phase I clinical trial for TTX-MC138, a therapeutic candidate aimed at treating metastatic cancer. The company has initiated dosing for the first patient in Cohort 4, marking a key advancement in the ongoing multi-center, open-label study. This trial aims to evaluate the safety and tolerability of escalating doses of TTX-MC138. Previously, ten patients were successfully dosed across the first three cohorts without significant safety issues or dose-limiting toxicities, and seven of these patients continue to receive treatment. The Safety Review Committee has approved the enrollment of additional patients in Cohort 3 to further strengthen the safety profile of the drug. The trial’s dose-escalation phase primarily focuses on assessing safety and tolerability, while the subsequent dose-expansion phase will evaluate potential anti-tumor activity. TTX-MC138 targets microRNA-10b, a significant factor in metastatic disease, and has shown promise in preclinical studies and a Phase 0 trial. The ongoing trial is structured to provide insights into the drug’s pharmacokinetic and pharmacodynamic profiles, aligning with earlier preclinical and Phase 0 outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.